Platelet-rich fibrin added to surgery for jaw bone damage caused by medicines
Tests adding L-PRF to surgery for medication-related osteonecrosis of the jaw, looking at wound healing.
Key facts
- Who runs it
- University Hospital, Toulouse
- Where
- France6 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Leukocyte- and Platelet-Rich Fibrin in the Surgical Treatment of Medication-related Osteonecrosis of the Jaw
- Status
- Not yet recruiting
- People taking part
- 150 people, planned
- Started
- Nov 2026
- Expected to end
- May 2029
- Type of study
- Interventional, 2 groups
- Treatments tested
- Surgery with the use of L-PRF
- Standard surgery
- Record updated
- 29 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with jaw bone damage caused by medicines (MRONJ) who need surgery under general anesthesia. It tests L-PRF, a material made from the patient's own blood, added to surgery.
- Age
- 18 Years and older
- Sex
- All
- Disease stage
- MRONJ stage 2 or 3 by AAOMS criteria, with a dead bone piece that must be removed under general anesthesia.
- Earlier treatment
- First-line treatments must have failed.
Main reasons for not taking part
- A tumour in the upper or lower jaw
- More than one MRONJ lesion
- Past radiotherapy to the head and neck
- Cannot have general anesthesia
- Life expectancy estimated at less than 6 months
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- MRONJ requiring surgical treatment according to AAOMS criteria (stage 2 or 3; failure of first-line treatments; sequestration of a necrotic bone block), the resection of which needs general anesthesia
- Affiliates or beneficiaries of a social security scheme
- Having given free and informed written consent
Who cannot take part
- History of cervico-facial radiotherapy
- Presence of a maxillo-mandibular neoplastic lesion
- Presence of several MRONJ lesions
- Contraindication to general anesthesia
- Reduced life expectancy (estimated at less than 6 months)
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Medication-related osteonecrosis of the jaw (MRONJ) is a rare but serious side-effect of antiresorptive therapies used in the management of bone diseases, such as osteoporosis or bone metastases. A surgical management can lead to a resolution of the disease, but with perfectible results. For this purpose, the use of autologous platelet concentrates (APC) can be useful. With this study, researchers aim to demonstrate the efficacy of L-PRF (Leukocyte- and Platelet-Rich Fibrin) as an adjunct to the surgical treatment of MRONJ in terms of wound healing.
The 2 groups in the trial
- Experimental groupTreatment being tested
Patients will benefit from surgery with the use of L-PRF.
Treatment: Surgery with the use of L-PRF
- Control groupOther group
Patients will benefit from standard surgical treatment.
Treatment: Standard surgery
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Use of Leukocyte- and Platelet-Rich Fibrin in the Surgical Treatment of Medication-related Osteonecrosis of the Jaw: a Randomized Controlled Trial
- Plain-language title
- Platelet-rich fibrin added to surgery for jaw bone damage caused by medicinesGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 29 October 2026